stockrow
Friday 6 November 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
169.01
9.19
−5.16%
Follow RGEN
Alert me
Repligen Corporation (RGEN) revenue by segment, product and region
Where the money comes from and where it goes
| Filtration Products | 403 | 54.56% |
|---|---|---|
| Chromatography Products | 153 | 20.75% |
| Proteins Products | 97 | 13.20% |
| Process Analytics Products | 81 | 11.00% |
| Other products | 3 | 0.45% |
| Royalty and other revenue | 0 | 0.04% |
| Gross margin | 52.32% | |
| Operating margin | 7.47% | |
| Pre-tax margin | 8.45% |
Revenue by product or service $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Filtration Products | 403 54.56% | 373 58.79% | 341 53.98% | 496 61.87% | 404 60.18% | 175 47.74% | 119 44.21% | 91 46.69% | 49 34.73% | 20 18.92% |
| Chromatography Products | 153 20.75% | 123 19.36% | 127 20.02% | 132 16.43% | 91 13.58% | 71 19.30% | 61 22.45% | 45 23.36% | 36 25.71% | 30 28.24% |
| Proteins Products | 97 13.20% | 74 11.73% | 103 16.36% | 114 14.26% | 124 18.45% | 83 22.75% | 69 25.53% | 54 28.02% | 54 38.21% | 55 52.34% |
| Process Analytics Products | 81 11.00% | 59 9.35% | 57 8.99% | 54 6.68% | 48 7.16% | 33 9.10% | 16 6.07% | — | — | — |
| Other products | 3 0.45% | 5 0.74% | 4 0.58% | 6 0.72% | 4 0.60% | 4 1.08% | 5 1.69% | 4 1.86% | 2 1.25% | 0 0.41% |
| Royalty and other revenue | 0 0.04% | 0 0.04% | 0 0.06% | 0 0.04% | 0 0.03% | 0 0.03% | 0 0.05% | 0 0.07% | 0 0.10% | 0 0.10% |
| Product | 738 | 634 | 632 | 801 | 670 | 366 | 270 | 194 | 141 | 104 |
| Revenue | 738 | 634 | 632 | 802 | 671 | 366 | 270 | 194 | 141 | 105 |